Real-world evidence for regulatory decision-making: updated guidance from around the world

被引:11
|
作者
Burns, Leah [1 ]
Le Roux, Nadege [2 ]
Kalesnik-Orszulak, Robert [3 ]
Christian, Jennifer [4 ]
Dudinak, Jennifer [5 ]
Rockhold, Frank [6 ]
Khozin, Sean [7 ]
O'Donnell, John [1 ]
机构
[1] Bristol Myers Squibb, Worldwide Hlth Econ & Outcomes Res, Princeton, NJ 08540 USA
[2] Bristol Myers Squibb, Regulatory Intelligence, Boudry, Switzerland
[3] Bristol Myers Squibb, Global Regulatory Sci, Princeton, NJ USA
[4] Target RWE, Durham, NC USA
[5] Bristol Myers Squibb, Global Regulatory Sci, Summit, NJ USA
[6] Duke Clin Res Inst, Dept Biostat & Bioinformat, Durham, NC USA
[7] MIT, Cambridge, MA USA
关键词
real-world evidence; real-world data; regulatory decision-making; real-world evidence regulatory frameworks; real-world data quality methods; real-world study methods; health technology assessment; SCIENTIFIC ADVICE;
D O I
10.3389/fmed.2023.1236462
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Leveraging the value of real-world evidence (RWE) to make informed regulatory decisions in the field of health care continues to gain momentum. Improving clinical evidence generation by evaluating the outcomes and patient experiences at the point-of-care would help achieve the ultimate aim of ensuring that effective and safe treatments are rapidly approved for patient use. In our previous publication, we assessed the global regulatory landscape with respect to RWE and provided a review of the regional availability of frameworks and guidance through May 2021 on the basis of 3 key regulatory elements: regulatory RWE frameworks, data quality guidance, and study methods guidance. In the current review, we have updated and elaborated upon recent developments in the regulatory RWE environment from a regional perspective under the same 3 regulatory elements stated above. In addition, we have also included a new category on procedural guidance. The review also discusses the perceived gaps and potential opportunities for future development and harmonization in this field to support framework establishment in regions without pre-existing RWE policies. Additionally, the article reviews current developments of health technology assessment (HTA) bodies pertaining to RWE and discusses the status of evidentiary alignment among regulators and HTA agencies.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] Real-World Evidence for Regulatory Decision-Making: Guidance From Around the World
    Burns, Leah
    Le Roux, Nadege
    Kalesnik-Orszulak, Robert
    Christian, Jennifer
    Hukkelhoven, Mathias
    Rockhold, Frank
    O'Donnell, John
    CLINICAL THERAPEUTICS, 2022, 44 (03) : 420 - 437
  • [2] The application of real-world evidence in drug regulatory decision-making
    Wicherski, Julia
    Haenisch, Britta
    BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ, 2024, 67 (02) : 255 - 256
  • [3] Comparison of two assessments of real-world data and real-world evidence for regulatory decision-making
    Yuan, Lily
    Rahman, Motiur
    Concato, John
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (01):
  • [4] Real-world endpoints to support regulatory decision-making
    Christian, Jennifer B.
    Warren, Edward J.
    Cameron, David
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 427 - 427
  • [5] Real-World Data Analytics Fit for Regulatory Decision-Making
    Schneeweiss, Sebastian
    Glynn, Robert J.
    AMERICAN JOURNAL OF LAW & MEDICINE, 2018, 44 (2-3) : 197 - 216
  • [6] Real-World Evidence in Regulatory Decision Making: Time for Evidence Integration
    Miksad, Rebecca A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 116 (05) : 1153 - 1155
  • [7] Expert survey on real-world data utilization and real-world evidence generation for regulatory decision-making in drug lifecycle in Korea
    Lee, Hankil
    Ahn, Hyeon-Soo
    Kwon, Sol
    Kang, Hye-Young
    Han, Euna
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (04):
  • [8] KEY CONSIDERATIONS FOR EVALUATING REAL-WORLD EVIDENCE IN SUPPORT OF FDA REGULATORY DECISION-MAKING
    Li, Jie
    INNOVATION IN AGING, 2022, 6 : 193 - 193
  • [9] Optimizing real-world evidence studies for regulatory decision-making and impact assessment in pharmacovigilance
    Ioakeim-Skoufa, Ignatios
    Atkins, Kerry
    Hernandez-Rodriguez, Miguel angel
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2025,
  • [10] Development of a Canadian Guidance for reporting real-world evidence for regulatory and health-technology assessment (HTA) decision-making
    Tadrous, Mina
    Aves, Theresa
    Fahim, Christine
    Riad, Jessica
    Mittmann, Nicole
    Prieto-Alhambra, Daniel
    Rivera, Donna R.
    Chan, Kelvin
    Lix, Lisa M.
    Kent, Seamus
    Dawoud, Dalia
    Guertin, Jason Robert
    Mcdonald, James Ted
    Round, Jeff
    Klarenbach, Scott
    Stanojevic, Sanja
    Vera, Mary A. De
    Strumpf, Erin
    Platt, Robert W.
    Husein, Farah
    Lambert, Laurie
    Hayes, Kaleen N.
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2024, 176